S
Shanghai Rendu Biotechnology Co Ltd
SSE:688193
Shanghai Rendu Biotechnology Co Ltd
SSE:688193
Price:
51.13
CNY
2.53%
Market Closed
Market Cap:
¥2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
Shanghai Rendu Biotechnology Co Ltd
SSE:688193
|
CN |
|
C
|
ChipMOS Technologies Inc
TWSE:8150
|
TW |
|
Aowei Holding Ltd
HKEX:1370
|
CN |
|
S
|
Shanghai Tianchen Co Ltd
SSE:600620
|
CN |
|
Payroll Inc
TSE:4489
|
JP |
|
G
|
Gatos Silver Inc
TSX:GATO
|
US |
|
Raiznext Corp
TSE:6379
|
JP |
|
Sajodongaone Co Ltd
KRX:008040
|
KR |
|
C
|
Compal Electronics Inc
TWSE:2324
|
TW |
Income Statement
Earnings Waterfall
Shanghai Rendu Biotechnology Co Ltd
Shanghai Rendu Biotechnology Co Ltd
Income Statement
Shanghai Rendu Biotechnology Co Ltd
Shanghai Rendu Biotechnology Co Ltd
Currency: CNY
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||
| Interest Expense |
0
|
0
|
1
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
292
N/A
|
299
+2%
|
322
+8%
|
309
-4%
|
304
-2%
|
249
-18%
|
214
-14%
|
181
-16%
|
123
-32%
|
124
+0%
|
131
+6%
|
177
+36%
|
173
-2%
|
|
| Gross Profit | ||||||||||||||
| Cost of Revenue |
(74)
|
(85)
|
(97)
|
(94)
|
(106)
|
(84)
|
(66)
|
(54)
|
(23)
|
(24)
|
(26)
|
(39)
|
(38)
|
|
| Gross Profit |
218
N/A
|
214
-2%
|
225
+5%
|
215
-5%
|
198
-8%
|
165
-17%
|
148
-10%
|
127
-14%
|
100
-21%
|
100
+0%
|
104
+4%
|
138
+33%
|
135
-2%
|
|
| Operating Income | ||||||||||||||
| Operating Expenses |
(149)
|
(149)
|
(172)
|
(181)
|
(183)
|
(182)
|
(174)
|
(157)
|
(113)
|
(109)
|
(113)
|
(170)
|
(170)
|
|
| Selling, General & Administrative |
(123)
|
(128)
|
(150)
|
(157)
|
(150)
|
(154)
|
(142)
|
(121)
|
(83)
|
(79)
|
(85)
|
(130)
|
(135)
|
|
| Research & Development |
(25)
|
(27)
|
(30)
|
(34)
|
(32)
|
(35)
|
(38)
|
(38)
|
(31)
|
(32)
|
(30)
|
(35)
|
(37)
|
|
| Depreciation & Amortization |
(8)
|
0
|
0
|
0
|
(11)
|
0
|
0
|
0
|
0
|
0
|
0
|
(11)
|
0
|
|
| Other Operating Expenses |
6
|
6
|
8
|
11
|
10
|
7
|
6
|
2
|
2
|
2
|
3
|
6
|
3
|
|
| Operating Income |
69
N/A
|
65
-6%
|
53
-18%
|
34
-36%
|
15
-57%
|
(17)
N/A
|
(27)
-58%
|
(30)
-14%
|
(13)
+57%
|
(9)
+35%
|
(8)
+1%
|
(32)
-279%
|
(35)
-9%
|
|
| Pre-Tax Income | ||||||||||||||
| Interest Income Expense |
3
|
3
|
7
|
11
|
14
|
16
|
15
|
16
|
13
|
14
|
13
|
17
|
17
|
|
| Non-Reccuring Items |
0
|
1
|
1
|
1
|
(1)
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(1)
|
0
|
|
| Total Other Income |
1
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
|
| Pre-Tax Income |
72
N/A
|
69
-5%
|
60
-13%
|
44
-26%
|
27
-40%
|
(2)
N/A
|
(12)
-593%
|
(15)
-26%
|
(0)
+99%
|
5
N/A
|
4
-10%
|
(15)
N/A
|
(18)
-19%
|
|
| Net Income | ||||||||||||||
| Tax Provision |
(8)
|
(7)
|
(7)
|
(7)
|
(3)
|
2
|
3
|
6
|
2
|
1
|
0
|
7
|
8
|
|
| Income from Continuing Operations |
65
|
62
|
54
|
37
|
23
|
0
|
(9)
|
(9)
|
2
|
6
|
5
|
(8)
|
(10)
|
|
| Net Income (Common) |
65
N/A
|
62
-4%
|
54
-14%
|
37
-31%
|
23
-37%
|
0
-99%
|
(9)
N/A
|
(9)
+0%
|
2
N/A
|
6
+253%
|
5
-24%
|
(8)
N/A
|
(10)
-32%
|
|
| EPS (Diluted) |
1.62
N/A
|
1.54
-5%
|
1.33
-14%
|
0.92
-31%
|
0.58
-37%
|
0
N/A
|
-0.22
N/A
|
-0.22
N/A
|
0.04
N/A
|
0.15
+275%
|
0.12
-20%
|
-0.2
N/A
|
-0.26
-30%
|
|
Switch to:
Switch to:
See Also
Discover More
